Wiskott-Aldrich Syndrome
A rare, X-linked primary immunodeficiency causing small platelets, easy bleeding, eczema, and recurrent infections, primarily affecting infant boys.
- X-Linked Inheritance
- Curative Transplant Options
- Specialist Immunology Review
- Most Common In
- Male infants (X-linked)
- Clinical Hallmark
- Thrombocytopenia, eczema, infections
- Affected Gene
- WAS
- Advanced Therapies
- Hematopoietic Stem Cell Transplant, Gene Therapy
Condition Overview
Wiskott-Aldrich Syndrome (WAS) is a rare, X-linked primary immunodeficiency caused by mutations in the WAS gene, which encodes a protein critical to the structure and function of blood cells, including platelets and immune cells.
The classic triad of WAS includes microthrombocytopenia (small, low platelet count leading to bleeding), eczema, and recurrent infections due to combined immune dysfunction. Because it is X-linked, it almost exclusively affects males, while female carriers are usually unaffected.
Severity varies from milder forms presenting mainly as X-linked thrombocytopenia to classic WAS with significant immune deficiency, autoimmune complications, and increased lymphoma risk later in life.
Types and Subtypes
WAS exists along a clinical spectrum determined largely by the specific WAS gene mutation and resulting protein function.
Symptoms and Signs
Symptoms typically appear in infancy and reflect the combination of low platelets, skin involvement, and immune dysfunction.
Causes and Risk Factors
WAS is caused entirely by genetic mutations affecting the WAS gene, with no known environmental or lifestyle contributors.
Diagnosis and Investigations
Diagnosis combines clinical features with specialized blood and genetic testing, ideally coordinated through a pediatric hematology-immunology team.
Disease Severity Classification
WAS does not use a tumor staging system; instead, a clinical severity scoring system is used to classify disease based on the extent of immune dysfunction and bleeding risk.
Standard Treatment Options
Management is individualized based on disease severity, ranging from supportive care for milder forms to curative transplant for classic disease.
Advanced and Emerging Treatment Options
For patients without a suitable matched donor or seeking alternatives to traditional transplant, newer cellular and gene-based therapies are expanding options.
Cellular Therapy
Hematopoietic Stem Cell Transplant (HSCT)
Transplant from a matched sibling, unrelated, or haploidentical donor remains the standard curative approach for classic WAS.
Gene Therapy
Autologous Gene-Corrected Stem Cell Therapy
Investigational approaches use the patient's own gene-corrected stem cells as an alternative to donor transplant, avoiding graft-versus-host disease risk.
Immunomodulation
Targeted Therapy for Autoimmune Complications
Biologic agents are being explored to manage autoimmune cytopenias and vasculitis associated with WAS.
Biomarkers and Precision Medicine
Laboratory and genetic markers help confirm diagnosis, predict severity, and guide treatment selection in WAS.
When a Second Opinion May Be Important
Given the complexity of balancing bleeding, infection, and transplant decisions, specialist input is valuable at several key points.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in WAS have improved substantially with earlier diagnosis and access to hematopoietic stem cell transplant, which can be curative for many patients with classic disease. Milder XLT forms often have a more favorable course with supportive management alone.
Supportive Care and Living With Wiskott-Aldrich Syndrome
Comprehensive supportive care helps reduce complications from bleeding and infection while families navigate diagnosis and, where appropriate, transplant.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families of children with Wiskott-Aldrich Syndrome access specialist review of diagnostic reports, second opinions on transplant timing, and coordination with experienced pediatric transplant centers.
Get a free case reviewFrequently Asked Questions
Wiskott-Aldrich Syndrome is a rare X-linked genetic disorder that causes low platelet counts, eczema, and recurrent infections due to combined immune dysfunction.
Early signs often include easy bruising or bleeding in infancy, persistent eczema-like rash, and frequent infections such as ear infections or pneumonia.
Because it is X-linked, WAS almost always affects boys, while female relatives may be unaffected carriers.
Diagnosis relies on blood counts showing small, low platelets, immune function testing, and genetic confirmation of a WAS gene mutation.
Hematopoietic stem cell transplant can be curative for many patients with classic WAS, particularly when performed earlier in life from a well-matched donor.
Supportive treatments include platelet transfusions, prophylactic antibiotics, immunoglobulin replacement, and eczema management for those not yet transplanted.
No. Unlike hemophilia, which involves a specific clotting factor deficiency, WAS involves both small, low platelets and broader immune system dysfunction.
Patients with longstanding, untreated classic WAS have an increased risk of lymphoma, which is one reason early transplant evaluation is often recommended.
Yes, genetic counseling and carrier testing can help families understand inheritance risk and plan future pregnancies.
Yes. CancerFax can help review medical reports, coordinate a second opinion on transplant timing, and connect families with hospitals experienced in treating WAS.
Get Expert Guidance on a WAS Diagnosis
CancerFax can help connect your family with specialist review and transplant centers experienced in treating Wiskott-Aldrich Syndrome.